MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41541-023-00693-z

Медицинская библиотека · NPJ vaccines · 2023

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.

Lyke Kirsten E, Atmar Robert L, Dominguez Islas Clara, Posavad Christine M, Deming Meagan E, Branche Angela R, Johnston Christine, El Sahly Hana M, Edupuganti Srilatha, Mulligan Mark J, Jackson Lisa A, Rupp Richard E, Rostad Christina A, Coler Rhea N, Bäcker Martín, Kottkamp Angelica C, Babu Tara M, Dobrzynski David, Martin Judith M, Brady Rebecca C, Frenck Robert W, Rajakumar Kumaravel, Kotloff Karen, Rouphael Nadine, Szydlo Daniel, PaulChoudhury Rahul, Archer Janet I, Crandon Sonja, Ingersoll Brian, Eaton Amanda, Brown Elizabeth R, McElrath M Juliana, Neuzil Kathleen M, Stephens David S, Post Diane J, Lin Bob C, Serebryannyy Leonid, Beigel John H, Montefiori David C, Roberts Paul C, DMID 21-0012 Study Group

СтатьяПеревод в очереди

Аннотация

As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.

Для цитирования: Lyke Kirsten E, Atmar Robert L, Dominguez Islas Clara, Posavad Christine M, Deming Meagan E, Branche Angela R, Johnston Christine, El Sahly Hana M, Edupuganti Srilatha, Mulligan Mark J, Jackson Lisa A, Rupp Richard E, Rostad Christina A, Coler Rhea N, Bäcker Martín, Kottkamp Angelica C, Babu Tara M, Dobrzynski David, Martin Judith M, Brady Rebecca C, Frenck Robert W, Rajakumar Kumaravel, Kotloff Karen, Rouphael Nadine, Szydlo Daniel, PaulChoudhury Rahul, Archer Janet I, Crandon Sonja, Ingersoll Brian, Eaton Amanda, Brown Elizabeth R, McElrath M Juliana, Neuzil Kathleen M, Stephens David S, Post Diane J, Lin Bob C, Serebryannyy Leonid, Beigel John H, Montefiori David C, Roberts Paul C, DMID 21-0012 Study Group. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.. NPJ vaccines. 2023. DOI: 10.1038/s41541-023-00693-z.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.